Is Viking Therapeutics (VKTX) Fully Priced On Book Value?

Viking Therapeutics has swung sharply in recent years, with a powerful long term share price run now meeting a bout of short term weakness. That raises a straightforward question for investors who care about downside risk: Is the stock price at roughly US$30 still grounded in what the balance sheet, and specifically its book value, can support?

• Over the past 5 years the stock has returned about 401%, which puts a lot of past optimism on the line when you start asking how much underlying net asset value is backing each share today.
• The recent US$575m capital raise in common stock and convertible notes gives Viking more cash to push its obesity and liver disease programs forward, yet it also adds fresh capital and potential future dilution that matter when you compare the share price with the firm’s equity base.
• There is a second opinion on Viking Therapeutics worth weighing. See what analysts think Viking Therapeutics's shares could be worth.

The issue now is whether today’s valuation for Viking Therapeutics is adequately supported by its book value when set against the industry average.

If you want a broader watchlist of stocks where valuation is cross checked against fundamentals, consider using a focused screener built around 28 high quality undervalued stocks.

Does Viking Therapeutics Look Pricey on Book Value?

P/B is usually a cleaner yardstick for Viking Therapeutics because there is no steady earnings base yet, so investors tend to anchor on what they are paying relative to equity on the balance sheet. On this score, the stock changes hands at about 8.7x book value, using the current P/B ratio of 8.7x.

That level sits well above both the broader biotech industry average P/B of around 2.1x and the peer group on roughly 3.8x. This means the market is paying a substantial premium to the sector’s typical backing per dollar of net assets. Despite the recent capital raise to fund VK2735 and other programs, which lifted cash and shareholder equity, the P/B still implies investors are assigning a rich valuation to Viking’s pipeline and future prospects relative to what is currently on the balance sheet. For anyone weighing the share price against book value, the gap to sector norms signals that the stock screens as overvalued on this metric and that the model is heavily penalising current losses, so the multiple is best read as a warning flag rather than a precise pricing guide. Explore the numbers behind Viking Therapeutics's P/B valuation.

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Viking Therapeutics' valuation puzzle sets up the role of Simply Wall St Narratives, which map out what kind of future for growth, profitability and earnings would need to play out for the current share price to look meaningfully higher or lower in hindsight. These narratives sit on the Community page.

Each narrative turns that into a clear, testable idea about the business, so you can track how the underlying story holds up over time rather than treating fair value as a static snapshot.

One of the top community narratives on Viking Therapeutics: 76% undervalued

"The large, global demand for obesity treatments is aligning with VK2735’s late-stage development in two formulations…"

Discover why this Narrative puts Viking Therapeutics at 76% undervalued.

The unresolved question for Viking Therapeutics investors

Valuation only tells part of the story for Viking Therapeutics, because recent research has also flagged specific concerns that sit outside the numbers and deserve a closer look before you get comfortable. Take a closer look at 4 warning signs (1 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com